Clear links have been established between occupational or therapeutic radiation exposure and breast cancer. Tamoxifen chemoprevention following radiation exposure may be able to reduce the risk of developing breast cancer later in life. In order to model carcinogenesis in this setting, an in vivo model of tamoxifen chemoprevention and tamoxifen failure in a radiation-induced rat mammary carcinoma model was characterized. Two hundred and twenty-seven 60-day-old female rats received whole body or sham exposure to ionizing radiation. Thirty days later long-term, continuous, tamoxifen chemoprevention was initiated in half the population and all animals were monitored over three and a half years for the development of mammary tumors. Mammary tumors were surgically removed and carcinomas were histologically identified and characterized. Results showed that tamoxifen chemoprevention decreased the incidence and prolonged the latency of radiationinduced mammary carcinomas. However, many individuals receiving tamoxifen chemoprevention developed their first carcinoma very late in life. These carcinomas shared morphological features distinct from the majority of carcinomas that developed in the absence of tamoxifen chemoprevention. Analyses of cell lines established from these carcinomas and immunohistochemisty of tumor sections revealed that the highest levels of Her2/neu expression were associated with in vivo tamoxifen exposure. Treatment of rat mammary carcinoma cells with an antirat Her2/neu monoclonal antibody (MAb 7.16.4) inhibited cell growth and this effect was more pronounced in the presence of tamoxifen. These studies suggest that carcinoma growth driven by the Her2/neu pathway may be associated with tamoxifen chemoprevention failure in the rat mammary carcinoma model. Additionally, strategies combining targeted Her2/neu antibodies, vaccines or drugs with estrogen pathway modification may be more effective in reducing breast cancer chemoprevention failures.
Clear links have been established between occupational or therapeutic radiation exposure and breast cancer. Tamoxifen chemoprevention following radiation exposure may be able to reduce the risk of developing breast cancer later in life. In order to model carcinogenesis in this setting, an in vivo model of tamoxifen chemoprevention and tamoxifen failure in a radiation-induced rat mammary carcinoma model was characterized. Two hundred and twenty-seven 60-day-old female rats received whole body or sham exposure to ionizing radiation. Thirty days later long-term, continuous, tamoxifen chemoprevention was initiated in half the population and all animals were monitored over three and a half years for the development of mammary tumors. Mammary tumors were surgically removed and carcinomas were histologically identified and characterized. Results showed that tamoxifen chemoprevention decreased the incidence and prolonged the latency of radiationinduced mammary carcinomas. However, many individuals receiving tamoxifen chemoprevention developed their first carcinoma very late in life. These carcinomas shared morphological features distinct from the majority of carcinomas that developed in the absence of tamoxifen chemoprevention. Analyses of cell lines established from these carcinomas and immunohistochemisty of tumor sections revealed that the highest levels of Her2/neu expression were associated with in vivo tamoxifen exposure.
Introduction
Women who receive radiotherapy for Hodgkins disease between 10 and 25 years of age are at particular risk of developing breast cancer as a second malignancy much later (420 years) in life (1, 2) . Hormonal factors such as early menopause or reduced exposure to hormonal therapy appear to result in a reduced risk of breast cancer following radiotherapy and these findings suggest that tamoxifen chemoprevention should be considered following certain radiation exposures (3) . Selective estrogen receptor modulators (SERMs) such as tamoxifen, significantly reduce the risk of breast cancer in women whose primary tumors are estrogen receptor positive by~40% (4, 5) .
Recent findings suggest that inhibition of ErbB family receptor signaling may help to reduce tamoxifen chemoprevention failures. Retrospective analyses of tumor metastases and adjuvant clinical studies suggest that Her2/neu overexpression is associated with tamoxifen resistance (6--8) and this is further supported by in vitro studies in which Her2/neu-transfected mammary cancer cells are rendered hormone independent (9, 10) . Recent evidence also suggests that an estrogen receptor co-activator AIB1 phosphorylated by Her2/neu, reduces the antagonistic activity of tamoxifen (11) . In light of these findings, patients who are both Her2/neu and estrogen-receptor positive may benefit from combined SERM-anti-Her2/neu therapeutic and/or chemopreventative approaches for the treatment and prevention of breast cancer (5) . A humanized anti-Her2/neu receptor monoclonal antibody, Herceptin, is currently being used in the treatment of Her2/neu receptor positive breast cancer patients (12) . Several newly developed compounds such as tyrosine kinase inhibitors and antibodybased small molecules exhibit similar, or greater, tumor growth inhibitory effects as Herceptin and may also have potential as chemopreventative agents (13, 14) . Their clinical application and toxic side effects are currently under investigation in preclinical and phase I clinical trials (15, 16) .
No model system has been characterized to examine the relationship between tamoxifen chemoprevention failure and Her2/neu expression. Systems most commonly used to study HER2/neu-targeted approaches involve the use of genetically engineered mice that over-express either the human or rat receptor (17, 18) . However, mammary tumors that result from the forced overexpression of Her2/neu in the mouse may not adequately reflect the natural progression of breast cancer and are of limited use in SERM treatment studies. Rat models of Her2/neu expression in the mammary gland have been extensively studied using retroviral vectors to deliver a mutated Her2/neu gene to the mammary epithelium (19--21) and rat lines have been developed that express Her2/neu as a transgene (22, 23) . However, studies of the natural expression of Her2/neu in rodent mammary carcinomas are limited. The female rat is now re-emerging as a breast cancer model because of its long-established predictive value in developing interventions against human breast cancer (24,25) combined with recent advances in rat genomics (23, 26) .
Rats exposed to ionizing radiation have a high incidence of mammary tumors, and like breast cancer in humans, some are tamoxifen-responsive and/or express HER2/neu (27) (28,29).
We have characterized a rat mammary carcinoma model to examine the relationship between tamoxifen chemoprevention failure and Her2/neu expression for radiation-induced breast cancer. We found that tamoxifen chemoprevention was effective in reducing the incidence and prolonging the latency of mammary carcinomas, which arise following radiation exposure. However, this effectiveness is diminished later in life and numerous tamoxifen-resistant carcinomas arise. Her2/neu was expressed at varying levels in all of the carcinomas with the highest levels of expression being found in tamoxifen-treated rats. Mammary carcinoma cells obtained from irradiated, tamoxifen-treated rats are also analogously growth inhibited when treated with anti-Her2/neu MAbs. Our findings in characterizing this relevant model provide new insights into the relationship between the estrogen pathway and Her2/ neu-targeting strategies for a combinatorial approach to the treatment and prevention of breast cancer.
Materials and methods

Animals
Sixty-day-old female Sprague--Dawley rats (Charles River, CD1) were sham exposed or exposed to 300, 500 or 900 cGy of whole body, photon radiation.
At 90 days, half of the rats at each radiation dose received subcutaneous sustained-release tamoxifen (TAM) pellets (Innovative Research, Sarasota, FL) designed to deliver 200 mg of tamoxifen per day for 60 days. At 150 days, and every 6 months thereafter for life, each TAM rat received a subcutaneous sustained-release pellet designed to deliver 20 mg of tamoxifen per day for 180 days. The pellets were placed subcutaneously on the dorsum of the neck. Animals were palpated and weighed regularly in order to detect new tumors and in order to control the weight gain of each group since decreased dietary intake, while on tamoxifen, has an independent effect on reducing incidence of mammary carcinomas in rats (30) . Dietary restriction was used to minimize the indirect effects that tamoxifen has on mammary tumor incidence through reduced weight gain. Rats were fed ad libidum if individual body weight remained at or below the average for the TAM-treated rats. Diet was restricted by 13% for individuals that were 0--5% over the average weight of the TAM rats and by 25% if rats weighed 45% more than the average of the TAM rats. Diet returned to ad libidum once individuals were brought within 5% of the average for TAM rats. This method of mild dietary restriction in the No TAM rats significantly decreased the incidence of mammary carcinomas compared with matched ad libidum fed groups that were irradiated with 0 or 500 cGy photons (unpublished). Palpable tumors were surgically excised under 1% isofluorane anesthesia and immediately fixed in formalin or frozen for later analysis. All rats were housed in a single room of a pathogen free facility maintained at 70 F and 30--70% relative humidity on a 12 h light--dark cycle. They were kept in solid bottom cages with filter tops and corn cob bedding. Animal protocols were designed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication pp. 8--125, revised 1996) and were approved by our Institutional Animal Care and Use Committee. A paired t-test was used to obtain P-values and determine the statistical significance of differences between groups.
Cell lines
Mammary tumors were sterilely minced in Dulbecco's modified essential medium (DMEM) (Life Technologies) and enzymatically dissociated with collagenase and Dnase treatment for 30--60 min. The cells were then centrifuged and resuspended in media containing 10% fetal bovine serum in DMEM supplemented with L-glutamine and penicillin/streptomyocin (growth media) (Life Technologies) and grown in a humidified incubator at 37 C with 5% CO 2 . Cells had been passaged at least 20 times before experiments were initiated. The MCF-7 human mammary cancer cell line is available from American Type Tissue Culture Collection (Manassas, VA).
Histology
Tumor tissues were fixed for at least 48 h in 10% buffered formalin, and transverse sections from the middle of each tumor were embedded in paraffin, sectioned at 5 mm, and stained with hematoxylin and eosin for histopathological evaluation. A histological grading pattern was applied in a blinded fashion to mammary carcinomas. A grading score of 1--3 was used with 1 ¼ 495% papillary, tubular or papillary-cystic pattern; 2 ¼ 5--50% solid pattern including cribiform, comedone, solid and undifferentiated; and 3 ¼ 450% solid pattern.
Immunohistochemisty: Her2/neu expression Anti-Her2/neu monoclonal antibody (MAb 7.16.4) (31) was used to detect the presence of the receptor in 5 m frozen sections of rat mammary carcinoma tissues. The MAb was biotinylated and diluted 1:50 according to manufacturer's instructions (DAKO Animal Research Immunohistochemistry Kit). Non-specific IgG2a antibodies (Sigma) was used as a negative control. Tissues were fixed in acetone, treated with biotin blocking buffer and peroxidase according to manufacturer's instructions (DAKO). Sections were then incubated with biotinylated antibodies for 15 min, followed by another 15-min incubation with streptavidin-peroxidase. DAB with substrate chromogen (DAKO) was added to the rinsed slides in order to detect bound MAb 7.16.4. Sections were subsequently counterstained for 10 s with Mayer's Hematoxylin solution (Sigma). Staining intensity was independently scored on a scale of 1--10 by two of the authors and background staining (IgG2a) scores were subtracted from MAb 7.16.4 stained sections to derive the total score to the agreement of both evaluators (IHC Net -- Table II) .
Focus formation assay
Cells were released from culture flasks with Trypsin-EDTA (Sigma) and resuspended at a concentration of 15 cells/ml in 10 ml of growth media and placed in 10-mm culture dishes. The cells were allowed to grow for 9 days at which point they were washed with phosphate buffered saline (PBS) (pH 7.4) and stained with 1 mg/ml p-iodonitrotetrazolium violet in DMEM overnight.
Flow cytometric analyses
Cells were released from tissue culture flasks and 50 000 cells were incubated in the presence of 20 mg/ml anti-Her2/neu (MAb 7.16.4). Binding was detected by anti-mouse immunoglobulin conjugated to a fluorescene label (Sigma Immunochemicals) and 8000 cells were analyzed per sample by flow cytometry. Replicates of three samples were analyzed.
Her2/neu transmembrane point mutation analyses
Procedures were performed according to Buzard et al. (32) and described briefly here. RNA was isolated from rat mammary tumor (RMT) cells using the RNeasy Mini-kit (Qiagen) and reverse-transcribed and amplified by reverse-transcription polymerase chain reaction (RT--PCR) using primers homologous to the rat neu transmembrane domain (Forward-CAGCCCGG-TGACATTCATCA; Reverse-TACTTCCGGATCTTCTGTCT). Forty cycles of amplification were performed (denatured at 95 C, annealed at 55 C and elongated at 72 C). The cDNA thus produced was digested with MnlI (New England Biologics) and analyzed by 10% polyacrylamide gel electrophoresis. The gel was stained with ethidium bromide and visualized under ultraviolet light. NIH 3T3 cells that were transfected with transforming rat Her2/neu cDNA were used as a positive control.
Cell viability assay: MTT Cells were released from culture flasks and resuspended at concentrations of 2000 cells/ml (RMT 50 and 56), 5000 cells/ml (RMT 91) and 1000 (NIH3T3-t-Her2/neu) in growth media and 100 ml were distributed to each well of a 96-well plate. Tamoxifen (Sigma), MAb 7.16.4, or combinations of both were added to respective wells at concentrations as indicated in the text. Five identically treated wells were seeded for each treatment group and replicated 96-well plates were analyzed for each day. On indicated days, the media from each well was replaced with 100 ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)(Sigma).
Cells were incubated in the MTT for 3 h at which point they were lysed in acidified isopropanol and colorimetric change in the media associated with viable cell numbers was quantitated by spectrophotometric analysis at 570 nm using a fluorescent plate reader (BioRad, Model 3550) (33) .
Western blots
The cells were lysed in 0.5 ml of lysis buffer (1% NP40, 0.5% deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.1 M sodium phosphate (pH 7.4), 200 U/ml of 2 mM EDTA, Aprotinin, 1 mM phenylmethylsulfonyl fluoride). The protein concentration of each sample was determined by the Bradford method (BioRad Protein Assay, Hercules, CA) and equal amounts of protein were loaded on a 10% SDS--PAGE. After electrophoresis, the proteins were transferred to PVDF membrane (Immobilon-P, Millipore, Bedford, MA). Blotting was performed using rabbit anti-estrogen receptor-a (MC-20) and b (H-150) (Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:500 in blocking buffer : TTBS (100 mM Tris--HCl (pH 7.5), 0.9% (w/v) NaCl and 0.05% Tween-20) with 5% powdered milk. Horse-radish peroxidase-conjugated anti-rabbit immunoglobulin (Amersham Pharmacia, Piscataway, NJ) diluted 1:1000 in blocking buffer was added to the blots after the primary antibody was washed with TTBS. Enhanced chemiluminescence (ECL) reagent and CL-X Posure film (Pierce, Rockford, IL) was used to visualize protein bands. The blots were stripped and the procedure was repeated with anti-b-actin antibodies (AC-74) Rat mammary carcinoma model (Sigma-Aldrich, St Louis MO). The blots were electronically scanned and band intensities were quantified using the Scion analysis program (Fredrick, MD).
Results
Tamoxifen chemoprevention of carcinomas induced by ionizing radiation
The effect of continuous tamoxifen chemoprevention in a rat mammary carcinoma model analyzing time to first carcinoma over the complete lifespan is shown in Figure 1 . In the absence of tamoxifen chemoprevention, ionizing radiation resulted in a marked increase in the cumulative incidence of first mammary carcinomas in female rats at all ages for 300, 500 and 900 cGy whole body exposure compared with sham-exposed individuals. Tamoxifen chemoprevention, initiated 30 days after exposure, decreased the cumulative incidence of mammary carcinomas at all three doses of ionizing radiation that were studied. The effect of tamoxifen on the mean carcinoma latency of each group is shown in Figure 2 . Carcinomas in the sham-irradiated TAM group (n ¼ 5 for TAM, n ¼ 5 for No TAM) had a slightly increased latency compared with the sham-irradiated No TAM group, but the trend failed to reach significance. However, tamoxifen clearly prolonged the latency of carcinomas that arose in irradiated rats. If all irradiated rats were analyzed as a group, the mean carcinoma latency for all receiving tamoxifen was 21.5 months compared with a mean carcinoma latency of 13.1 months for all irradiated rats that did not receive tamoxifen (P 0.0001). If divided according to dose, tamoxifen significantly prolonged the latency of mammary carcinomas at 300 and 500 cGy exposure and showed a trend toward prolonged latency at the 900 cGy dose. We conclude that tamoxifen is effective as a chemopreventive against radiation-induced mammary carcinomas even when initiated 30 days following radiation exposure.
Effectiveness of tamoxifen chemoprevention during aging
In this lifetime study, we had the opportunity to examine the effectiveness of tamoxifen chemoprevention both early and late following radiation exposure. The results of longitudinal analysis of new carcinoma incidence are summarized in Table I . Overall, tamoxifen had a positive impact on mean survival in both irradiated and non-irradiated females. In addition, tamoxifen was remarkably effective in preventing early carcinomas as no carcinomas occurred in any irradiated females during the first 12 months following irradiation compared with a 28.9% incidence of new mammary carcinomas in irradiated females. At 13--24 months after irradiation, tamoxifen chemoprevention was less effective, but still reduced the incidence of new mammary carcinomas by~50% in irradiated females (25/56 with No TAM compared with 19/80 with TAM). However, tamoxifen chemoprevention failed to reduce the incidence of new mammary carcinomas in the oldest females at (35) . The mammary carcinomas were classified as either predominantly papillary (low grade) or as solid if they had a significantly solid growth pattern (high grade). A histological pattern grade (1--3) was assigned to each carcinoma based on its histological pattern of growth. The mean histological pattern grade was higher in the carcinomas that arose in the presence of tamoxifen compared with carcinomas that arose in the absence of tamoxifen. In addition, while papillary and solid carcinomas arose in both TAM and No TAM groups at a variety of ages, the majority of carcinomas that arose in the presence of tamoxifen were classified as having a solid pattern (57%) compared with a papillary pattern (43%). This was different from the majority of the carcinomas which arose in the absence of tamoxifen which had predominantly a papillary pattern (77%).
We examined the effectiveness of tamoxifen chemoprevention against these two types of carcinomas by examining the mean latency of each tumor type in the presence or absence of tamoxifen. The results in Table II revealed that mean latency of papillary carcinomas was significantly increased by tamoxifen chemoprevention (13.2 months versus 22.7 months; P 5 0.0001). However, the latency of solid tumors was not significantly altered by tamoxifen chemoprevention (P ¼ 0.0986). Interestingly, in the No TAM group, the carcinomas that had a solid pattern of growth exhibited a longer latency than carcinomas of the papillary subtype. We conclude that the incidence of carcinomas was increased in irradiated rats, and those exposed to long-term tamoxifen chemoprevention developed tumors later in life.
Her-2/neu expression in rat mammary carcinomas
In order to further examine the relationship between tamoxifen chemoprevention and expression of Her-2/neu in mammary tumors, a subset of mammary carcinomas excised from tamoxifen-treated and untreated irradiated rats was compared for Her-2/neu expression. Consecutive tissue sections were stained with MAb 7.16.4 and an isotype control (IgG2a) and staining intensity of each slide was independently evaluated by two of the authors (N.P. and D.H.) who were blinded to the treatment groups (Table II and Figure 3 ). Scores never varied by 42 points between the two evaluators and a consensus score was determined for each slide with minor discrepancies. Table III demonstrates that tumor tissues with the highest expression level of Her2/neu expression were taken from tamoxifen-treated rats. Low or intermediate Her2/neu expression in the mammary tumors occurred in both the presence and absence of tamoxifen chemoprevention in the tissues analyzed.
In order to investigate the effects of tamoxifen and antiHer2/neu targeted chemoprevention at the cellular level, cell lines were developed from mammary tumors of post-irradiated rats and one sham-irradiated rat (Table IV) . Cultures were established from primary tumors and passaged for a minimum of 20 times before assays were performed. Cell growth and morphology were characteristic of mammary carcinoma cells. Flow cytometric analysis of six of the RMT cell lines using anti-Her2/neu monoclonal antibody (MAb) 7.16.4 revealed that the tyrosine kinase receptor was expressed in varying amounts in all of the cell lines (Figure 4) . The cell line with the highest level of Her2/neu expression (RMT 50) was derived from an irradiated tamoxifen-treated rat, while that A B Fig. 3 . Model of immunohistochemical analysis of Her-2/neu expression in a rat. Mammary tumor paraffin embedded mammary tumor tissue taken from rat no.538 was analyzed as described in Table II with the lowest expression level (RMT 91) was obtained from non-tamoxifen-treated, irradiated rat. Similar to results observed in the immunohistochemistry analysis of a different subset of tumors, RMTs with intermediate levels of Her2/neu expression were derived from both treatment groups. cDNAs from each of the cell lines were also analyzed by the RT--PCRMnlI digestion assay to determine if a transforming point mutation in the transmembrane codon 664 (T ! A) of Her2/ neu may have been associated with the development of mammary tumors in the irradiated rats (32) . Unlike neurologic tumors in mutagen-treated rats and hamsters, there was no evidence of this mutation in the transmembrane codons of cDNAs obtained from RMTs (data not shown). Tamoxifen exposure history in the rat affected the in vitro growth characteristics of the RMT cell lines. The ability of cells to form foci when seeded at low density is characteristic of a transformed phenotype (36) . When this assay was used to compare the RMTs, cell lines derived from two of the tamoxifen-treated rats (RMT 58 and 87) formed the largest and most foci, whereas the RMTs from rats that did not receive the chemopreventative formed fewer foci (RMT 99 and 18) or none at all (RMT 91) ( Figure 5 ). Although RMT 50 (tamoxifen-treated rat) had the highest level of Her2/neu expression level, the number of foci and staining intensity was less than expected. However, RMT 50 grew at a much faster rate, reached a higher density and had a higher level of Her2/neu expression, when compared with RMTs derived from untreated rats (RMT 56 and 91) ( Figure 6 , compare 0 mM Tamoxifen doses-A, B and C). Although the growth rates of RMT 56 and RMT 91 were similar during the first 5 days after seeding, RMT 91 cells began to die over the following 2 days, whereas the viability of RMT 56 remained stable at its peak during this time period (data not shown). We conclude that at least a subset of mammary carcinomas that develop after radiation exposure and long-term tamoxifen chemoprevention express high levels of Her-2/neu.
Estrogen receptor expression in RMT cell lines
Western blot analysis was performed to determine if in vivo tamoxifen exposure influenced estrogen receptor expression Rat mammary carcinoma model in six RMT cell lines. Estrogen receptor-a (ERa) was expressed in all of the cell lines with the highest relative level in the cell line derived from the non-irradiated, untreated rat ( Figure 7 , RMT 99). Similar to that of some human cell lines (37), but not MCF-7s, a lower molecular weight form of ERa was observed in most of the RMTs. Estrogen receptor b (ERb), which has been speculated to play a role in mammary tumorogenesis (38) , was also detected in the RMTs (Figure 7) . Variation in the size of ERb has been described in human breast cancer cell lines (39) ; it also occurs in RMTs, as two predominant isoforms of ERb were detected in RMT 99 ( Figure 7) . In summary, estrogen receptor expression or subtype (a or b) in RMTs was not consistently affected by in vivo tamoxifen selection pressure, but heterogeneity occurs, as in human mammary cancer tissues and cell lines.
RMT cell response to tamoxifen and Her-2/neu targeted treatment Because the RMTs expressed both Her-2/neu and estrogen receptors, selected cell lines were investigated to develop an in vitro assay to study cell sensitivity to receptor targeted therapies. Each of the three cell lines that were analyzed had different growth characteristics in the presence of increasing doses of tamoxifen ( Figure 6 ). All were significantly inhibited by 5 mM of tamoxifen. Interestingly, high concentrations of tamoxifen (20 mM) had an agonistic effect on RMT 50 and 56, but not upon RMT 91. Briefly, there were no obvious associations between estrogen receptor and Her-2/neu expression levels and tamoxifen sensitivity. However, the heterogeneity of these cell lines may be useful in studies to elucidate the mechanisms of receptor interactions that govern cellular responses to treatment.
Having demonstrated that the response of RMTs to tamoxifen treatment varies, and that p185
Her2/neu is expressed on their cell-surface, the potential of this tyrosine kinase receptor to serve as an anticancer target in this model was further investigated in vitro. RMTs and rat Her2/neu transformed NIH 3T3 fibrocytes were exposed to 50 and 200 mg/ml MAb 7.16.4 ( Figure 8 ). In order to allow sufficient time for growth differences to be detected, cells were seeded at a lower density than the previous MTT assays. RMT 91 did not grow well at this lower density and was, therefore, not included in our analysis.
In each of the cell lines analyzed, the higher dose of MAb 7.16.4 was growth inhibitory as evidenced by the decreased slope of the growth curve. By 6 days post-seeding, the growth rates of NIH3T3--Her2/neu, RMT 50 and RMT 56 were significantly lower than their respective controls and 50 mg/ml treatment groups (P 5 0.05). However, antibody treatment alone was insufficient to completely abolish cell growth and by 7 days post-seeding, the number of viable cells in high dose treatment groups of each of these lines was not significantly different than some of the controls (P 5 0.05). These results are concurrent with observations in MAb 7.16.4-treated athymic mice, in that growth of transplanted NIH3T3--Her2/neu cells was inhibited, but not killed (40).
As described above, tamoxifen treatment significantly delayed the onset and decreased the incidence of mammary tumors in irradiated rats, but did not completely inhibit their occurrence. In order to test the hypothesis that combined therapies may be a more effective means of cancer treatment and further evaluate the potential of this model, the effects of combined tamoxifen-anti-Her2/neu treatment upon RMT growth in vitro was analyzed ( Figure 9 ). The low doses of tamoxifen (0.25 mM) and MAb 7.16.4 (50 mg/ml) applied independently to the RMTs for this study were insufficient to cause significant decreases in cell growth. However, when treatments were combined, growth of RMT 50 cells was markedly inhibited throughout the duration of the study and the number of viable cells after 10 days of combined treatment was significantly lower than the other experimental groups ( Figure 9A ). Because the RMT 56 cells do not reach the same high density as the RMT 50 cells in this assay, differences between experimental groups could not be discerned at the lower treatment doses ( Figure 9B) . If, however, the concentration of tamoxifen and MAb 7.16.4 were increased (0.5 mM and 200 mg/ml, respectively), the synergistic effect of the combined treatment upon RMT 56 could also be appreciated ( Figure 9C ). Similar to our previous results, MAb 7.16.4 alone obviously delayed RMT 56 cell growth during the first 8 days of treatment, but cell numbers had markedly increased during the next 2 days. This is in contrast to the tamoxifenMAb7.16.4-treated cells in which no cell growth was noted throughout the study. The sharp decline in viable cell numbers in the tamoxifen and tamoxifen-IgG2a-treated groups from days 8 to 10 was due to cell death after peak cell concentrations had been reached on day 8. In each of these studies, the combined tamoxifen-Mab 7.16.4 treatment appeared to be toxic to the RMTs upon microscopic observation and the cells were unable to recover and grow.
Discussion
The rat model provides an excellent setting for the development of combinatorial breast cancer treatments and chemopreventives that target estrogen and/or Her2/neu receptor signaling pathways. The results reported here, and those of others, demonstrate that the onset and incidence of mammary carcinomas in irradiated or mutagen-treated rats is markedly reduced in the presence of tamoxifen chemoprevention (29, 41) . We also found that the highest expression levels of Her2/neu tend to be associated with cell lines and tumors obtained from tamoxifen-treated rats (Table III) Ã Mean absorbance (540 nm) which was significantly less than other treatment groups. ANOVA (P 5 0.05), Tukey 95% Simultaneous Confidence Interval.
Rat mammary carcinoma model expression is associated with tamoxifen treatment resistance and a more aggressive tumor cell phenotype (42) (9, 43, 44) . However, similar to breast cancer in humans, the positive association between tamoxifen selection, Her2/neu expression and cell growth characteristics is not steadfast, and other genetic variables are also likely to influence cellular phenotype.
ER expression was detected in the RMTs that were obtained from the tamoxifen-treated rats (Figure 7 ; RMT50 and 87). These results are similar to those of human clinical studies in which ER expression is retained in more than half of acquired tamoxifen-resistant breast cancer cases (45) . Mutations that cause tamoxifen bound estrogen receptor to adopt an activating conformation have also been proposed as a method by which selection for tamoxifen-resistant cells can occur without affecting gene expression levels (46, 47) . Yao et al. (48) found that MCF-7 cells grown in the presence of tamoxifen for 51 year would switch from a growth inhibitory to a growth stimulatory response to the anti-estrogen treatment. Tamoxifen's agonistic effect was also observed in our RMT cell lines when exposed to high doses of anti-estrogen in vitro (in Figure 6 compare A and B) .
Multiple molecular weight forms of both the ERa and ERb were observed on western blots. Heterogeneous expression of 16 splice variants of ERa was also identified in human breast cancer tissues (49) and one of these variants was shown to have constitutive transactivating properties (50) . Additionally, expression of ERa receptor variants was also shown to be associated with human breast tumors when compared with normal mammary tissue (51) . The significance of splice variants and receptor isoform heterogeneity in breast cancer prognosis and response to tamoxifen therapy is currently poorly understood and further studies using the resources developed here are likely to provide additional insights.
Transgenic mouse models that over express Her2/neu are commonly used in studies involving Her2/neu targeted approaches to cancer treatment and prevention. However, the forced expression of Her2/neu in the transgenic mouse models limits their application in studies aimed at elucidating mechanisms of immunotherapeutic or chemopreventative resistance, whereas tumor development in the irradiated rat is more likely to mimic that of the cancer patient. Furthermore, MAb 7.16.4-treated rats have recently been used as a model for Trastuzumab (anti-Her2/neu therapeutic antibody)-induced cardiotoxicity in people (Gabrielson, Peterson et al., in preparation), further supporting the role of the irradiated rat as an in vivo model for Her2/neu targeted approaches to cancer treatment, prevention and toxicity.
The mechanism by which MAb 7.16.4 inhibits tumor cell growth and causes cardiomyopathy in the rat is likely to be similar to that which occurs in humans, as its structure and epitopes are similar to that of the therapeutic antibody Herceptin (52) . Because mammary tumor and heart tissue in the rat and humans respond to anti-Her2/neu approaches similarly, this model would be most appropriate for the therapeutic and toxicologic evaluation of many newly developed anticancer drugs which target the Her2/neu signaling pathways, such as antibody-based small molecules (13) and tyrosine kinase inhibitors (53) . While not ideal due to long latency periods, the radiation-induced mammary carcinoma model in rats described here offers perhaps a more accurate, predictive means to model complex events involving carcinogenesis, tamoxifen resistance and aging in human breast cancer.
Combined approaches to cancer treatment and prevention are often more effective than mono-therapeutic strategies. Our results indicate that there is a synergistic tumoricidal effect when RMTs are cultured in the presence of tamoxifen and antiHer2/neu MAbs. These results are similar to studies in which tamoxifen sensitivity of human MCF-7 breast cancer cells was increased with anti-Her2/neu antibodies or blockade of the tyrosine kinase receptor pathways (53, 54) . Further studies in the irradiated rat could be used to determine whether the synergistic effects of the combined treatment would be sufficient to lower the anti-Her2/neu MAb concentration enough to avoid cardiotoxic effects and yet maintain a high level of tumor cell killing. Clinical trials in people are also currently were seeded in five replicate plates and incubated with 0.25 mM tamoxifen (T), 50 mg/ml MAb 7.16.4 (7), 50 mg/ml (IgG2a), without antibody (Ab-) or any combination of these as indicated. (C) 0.5 mM tamoxifen, 200 mg/ml MAb 7.16.4 and 200 mg/ml IgG2a were used. The MTT assay was performed on one of the plates at each of the specified days to determine the relative numbers of viable cells in each group. Replicates of five were analyzed for each treatment group on each day and the means are represented.
Ã Mean absorbance (540 nm) which was significantly less than other treatment groups. ANOVA (P 5 0.05), Tukey 95% Simultaneous Confidence Interval.
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underway to investigate the effectiveness of Trastuzmab (Herceptin) in combination with paclitaxel, platinum and taxanes, and anthracyclines with less cardiotoxicity, such as liposomal doxorubicin (reviewed in ref. 55 ). Additionally, Her2/neu vaccines are currently being investigated in mouse models for potential therapeutic and immunopreventative use (56, 57) . As shown here, the irradiated rat model can serve as an invaluable model as a means to evaluate the effectiveness of these anticancer approaches while providing useful information on their cardiotoxic effects.
